key: cord-0966562-hyck4wg8
authors: Sivapalasingam, Sumathi; Lederer, David J; Bhore, Rafia; Hajizadeh, Negin; Criner, Gerard; Hosain, Romana; Mahmood, Adnan; Giannelou, Angeliki; Somersan-Karakaya, Selin; O’Brien, Meagan P; Boyapati, Anita; Parrino, Janie; Musser, Bret J; Labriola-Tompkins, Emily; Ramesh, Divya; Purcell, Lisa A; Gulabani, Daya; Kampman, Wendy; Waldron, Alpana; Gong, Michelle Ng; Saggar, Suraj; Sperber, Steven J; Menon, Vidya; Stein, David K; Sobieszczyk, Magdalena E; Park, William; Aberg, Judith A; Brown, Samuel M; Kosmicki, Jack A; Horowitz, Julie E; Ferreira, Manuel A; Baras, Aris; Kowal, Bari; DiCioccio, A Thomas; Akinlade, Bolanle; Nivens, Michael C; Braunstein, Ned; Herman, Gary A; Yancopoulos, George D; Weinreich, David M
title: Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19: A Randomized Clinical Trial
date: 2022-02-26
journal: Clin Infect Dis
DOI: 10.1093/cid/ciac153
sha: 4afedc53d4c578f4dff311829f5a3f2051df0d45
doc_id: 966562
cord_uid: hyck4wg8

BACKGROUND: Open-label platform trials and a prospective meta-analysis suggest efficacy of anti–IL-6R therapies in hospitalized patients with COVID-19 receiving corticosteroids. This study evaluated the efficacy and safety of sarilumab, an anti–IL-6R monoclonal antibody, in the treatment of hospitalized patients with COVID-19. METHODS: In this adaptive, phase 2/3, randomized, double-blind, placebo-controlled trial, adults hospitalized with COVID-19 (ClinicalTrials.gov: NCT04315298) received intravenous sarilumab or placebo. The phase 3 primary analysis population included patients with critical COVID-19 receiving mechanical ventilation randomized to sarilumab 400 mg or placebo. The primary outcome was proportion of patients with ≥1-point improvement in clinical status from baseline to day 22. RESULTS: There were 457 and 1365 patients randomized and treated in phases 2 and 3, respectively. In phase 3, patients with critical COVID-19 receiving mechanical ventilation (n = 298; 28.2% on corticosteroids), the proportion with ≥1-point improvement in clinical status (alive, not receiving mechanical ventilation) at day 22 was 43.2% in sarilumab and 35.5% in placebo (risk difference +7.5%; 95% CI, –7.4 to 21.3; P = .3261), a relative risk improvement of 21.7%. In post-hoc analyses pooling phase 2 and 3 critical patients receiving mechanical ventilation, the hazard ratio for death in sarilumab versus placebo was 0.76 (95% CI, .51–1.13) overall and 0.49 (95% CI, .25–.94) in patients receiving corticosteroids at baseline. CONCLUSIONS: This study did not establish the efficacy of sarilumab in hospitalized patients with severe/critical COVID-19. Post-hoc analyses were consistent with other studies that found a benefit of sarilumab in patients receiving corticosteroids.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus first identified in December 2019, is the causative agent of coronavirus disease 2019 . While most patients with COVID-19 have mild disease, the leading cause of hospitalization and death is respiratory failure, including acute respiratory distress syndrome [1, 2] . A key driver of this deterioration may be a dysregulated inflammatory response [3] based on the observation of elevated circulating levels of inflammatory mediators such as C-reactive protein (CRP) and interleukin-6 (IL-6) [4, 5] . Early in the pandemic, small, uncontrolled studies reported that treating hospitalized patients with COVID-19 with 2 different IL-6 receptor (IL-6R)-blocking antibodies, tocilizumab and sarilumab, resulted in potentially dramatic clinical improvement [6] [7] [8] [9] [10] [11] . More recently, 2 platform trials found that tocilizumab or sarilumab may improve clinical outcomes in patients with COVID-19, the majority of whom were also receiving corticosteroids [12, 

We conducted an adaptive, phase 2/3, randomized, double-blind, placebo-controlled, multicenter trial (Supplementary Figure 1) . 62/65 sites enrolled patients; see list of sites in Supplementary Material). Since the trial was being conducted during a pandemic with a novel coronavirus, the protocol allowed adaptations, including closing treatment arms or randomization strata, modification of the provisional phase 3 endpoints, and sample size re-estimation before phase 3 database lock and study readout.

Eligible patients were ≥18 years of age and hospitalized with laboratory-confirmed SARS-CoV-2 infection requiring supplemental oxygen and/or assisted ventilation (see 

In phase 2, patients were randomized 2:2:1 to IV sarilumab 400 mg, sarilumab 200 mg, or placebo (for flow diagram of phase 2 see Supplementary Material, Phase 2 Study Results). Randomization was stratified by corticosteroid use and disease severity (severe, critical, multi-system organ dysfunction [MSOD] , and immunocompromised state). "Severe" COVID-19 was defined as patients receiving low-flow supplemental oxygen. "Critical" COVID-19 was defined as requiring supplemental oxygen by nonrebreather mask or high-flow nasal device, non-invasive ventilation, invasive mechanical ventilation, or management in an intensive care unit. "Multi-system organ dysfunction" (MSOD) was defined as use of vasopressors, extracorporeal life support, or renal replacement therapy.

A summary of protocol amendments and study adaptations are found in the Supplementary Material. A pre-specified phase 2 interim analysis of 457 patients suggested potential benefit of sarilumab 400 mg in patients only in the critical stratum [14] (for final Phase 2 results please see Supplementary Material, Phase 2 Study Results). Subsequently, the Independent Data Monitoring Committee recommended discontinuation of enrollment into the severe and MSOD strata and elimination of the 200-mg dose. Thereafter, the phase 3 protocol was amended (Supplementary Figure 1) to restrict enrollment to critical patients receiving mechanical ventilation, critical patients not on mechanical ventilation, severe patients, patients on MSOD and immunocompromised patients with further randomization (2:1) to sarilumab 400 mg and placebo (cohort 1; Figure 1 , n = 1407) and to add 2 new cohorts of critical patients receiving mechanical ventilation randomized to sarilumab 800 mg or placebo (cohort 2;

Supplementary Material, Phase 3 (Cohort 2) Study Results, n = 33); critical patients not receiving mechanical ventilation, but requiring high-flow oxygen or non-invasive ventilation, were randomized to sarilumab 800 mg or placebo (cohort 3; Supplementary Material, Phase 3 (Cohort 3) Study Results, n = 9). In addition, the following adaptations were implemented prior to database lock: the phase 3 primary analysis population was changed to patients randomized to the critical stratum receiving mechanical ventilation (MV) (without extracorporeal membrane oxygenation [ECMO]) who were randomized to the sarilumab 400-mg group or placebo, the primary endpoint was changed from the time to ≥2-point improvement in clinical status using a 7-point ordinal scale to the   proportion with ≥1-point improvement from baseline to day 22, and the sample size was re-calculated.

Results from the phase 3 immunocompromised stratum (n = 35 patients randomized and treated) are not shown; results for cohorts 2 and 3 (sarilumab 800 mg) are reported in the Supplementary Material.

Following the interim analysis from the phase 2 part of the study, the pre-specified primary endpoint for phase 3 cohort 1 was the proportion of critical patients receiving MV at baseline with ≥1-point improvement in clinical status on a 7-point ordinal scale from baseline to day 22 (Clinical Status Scale in the Supplementary Material) [15] . In this population, a 1-point improvement indicates that the patient was alive and no longer receiving MV. Other pre-specified endpoints included the proportion of patients who died by day 60 and the proportion of patients who recovered (discharged or alive without supplemental oxygen use) by day 22. All outcomes were assessed by the site investigators, who were blinded to treatment assignment and serum IL-6 levels conducted at a central laboratory. Safety endpoints are described in the Supplementary Material.

See Supplementary Material.

Statistical details are provided in the Supplementary Material and the statistical analysis plan.

The phase 3 primary analysis population included all patients with critical COVID-19 receiving MV without ECMO at baseline who were randomized to the sarilumab 400-mg or placebo groups.

Post-hoc analyses were conducted in the pooled data from phase 2 and phase 3 (cohort 1) to descriptively analyze the endpoints of the proportion of patients with ≥1point improvement in clinical status to day 22, proportion alive and not receiving MV, and time to death. All post-hoc analyses were unstratified.

From the period of March 18, 2020, to July 2, 2020, 457 patients were randomized and (25.4%) were randomized to the severe stratum, and 233 (17.1%) were randomized to the MSOD stratum. The median age of patients in the critical stratum was 61 years, 68% were male, and the median duration of illness was 9.0 days. The median serum CRP, serum IL-6 concentration, and viral load in nasopharyngeal swabs were 168.80 mg/L, 110.91 pg/mL, and 3.95 log 10 copies/mL, respectively. At randomization, 34.3% of critical patients were receiving systemic corticosteroids, and this was balanced across treatment groups (Table 1) .

Demographics and baseline characteristics for phase 3 severe and MSOD strata and for the pooled phase 2/3 dataset are presented in Supplementary Tables 2 and 3, respectively.

In the pre-specified primary analysis among critical patients receiving MV, 43.2% of patients in the 400-mg group and 35.5% patients in the placebo group had ≥1-point improvement in clinical status (alive not receiving MV) at day 22 (risk difference [RD] +7.5%; 95% CI, -7.4-21.3; P = .3261; Table 2 ; Figure 2A ), representing a relative risk improvement of 21.7%.

Among critical patients receiving MV at baseline, mortality by day 29 was 36.4% in the 400-mg group and 41.9% in the placebo group (RD -5.5%; 95% CI, -20.2-8.7; relative risk reduction 13.3%; key secondary endpoint) and mortality by day 60 was 39.4% in the sarilumab 400-mg group and 51.6% in the placebo group (RD -11.9%; 95% CI, -26.4-2.9; relative risk reduction 23.7%; Supplementary Table 4 ). Time to death in critical patients receiving MV at baseline is shown in Table 4 ).

There was no evidence of efficacy of sarilumab compared with placebo in severe or MSOD patients (Supplementary Table 5 ; Figures 2 and 3A). Figure 2C ).

In the phase 3 portion of the study in critical patients, the safety profiles of sarilumab 200 mg and 400 mg were comparable and were similar to placebo (Supplementary Table 6 ). Adverse events were consistent with advanced COVID-19 and its complications. Serious adverse events (SAEs) of cardiac arrest, COVID-19, respiratory failure, acute respiratory failure, septic shock, and acute kidney injury were reported in a similar proportion of patients in the sarilumab dose groups in comparison with placebo group, suggesting that these events were related to COVID-19 (Table 3) .

Adverse events of special interest (AESIs) reported in more than 5% of the patients in any treatment group were elevations of liver function tests, reported numerically more often in patients receiving sarilumab than placebo ( Table 3) . None of the liver transaminase elevation cases met Hy's law criteria.

In the phase 3 portion of the study, patients with severe disease or MSOD exhibited a similar safety profile to critical patients, and no new safety findings were observed (Supplementary Table 7) . Numerically, more patients reported elevation of liver function tests and SAEs in the sarilumab 200-mg and 400-mg dose groups in comparison with placebo (Supplementary Table 8) , which is expected, based on the known safety profile of sarilumab [16] .

In phase 3 cohort 1 of this phase 2/3 clinical trial conducted early during the COVID-19 pandemic, a numerically lower proportion of critical patients receiving mechanical ventilation in the sarilumab 400 mg had died by day 29 compared with placebo (36.4% vs 41.9%, respectively). This was a smaller effect than that observed with dexamethasone in the RECOVERY trial [17], and sarilumab did not lead to significant improvement in clinical status or mortality in hospitalized patients with COVID-19, the majority of whom were not receiving corticosteroids as SOC. There was also no benefit of sarilumab seen in patients receiving either low-or high-flow supplemental oxygen or non-invasive ventilation. It is important to note that since the majority of our enrollment in our study was prior to demonstration of the clinical utility of corticosteroids in COVID-19, only a minority of patients in our trial (~30%) were receiving concomitant corticosteroids. Therefore, these overall outcomes may not be generalizable to the hospitalized population receiving sarilumab in addition to corticosteroids as part of SOC.

In our post-hoc analyses where we pooled phase 2 and 3 datasets, critical patients receiving MV at baseline had a higher mortality rate of 68% with steroids alone (placebo group) compared with 44% with steroids and sarilumab 400 mg. An additive benefit of anti-IL-6R therapy to corticosteroids in patients with COVID-19 has previously been reported in 2 platform trials. The REMAP-CAP trial, in which >90% of patients were receiving corticosteroids as part of SOC, reported a mortality benefit of tocilizumab and sarilumab compared with SOC alone in hospitalized patients requiring organ support [12, 18] . The RECOVERY trial in hospitalized patients with COVID-19 with hypoxemia and CRP >75 mg/L, in which 82% of patients were receiving corticosteroids as SOC, demonstrated that tocilizumab led to a statistically significant reduction in mortality (29% in the tocilizumab group vs 33% in SOC only). Tocilizumab treatment of patients not receiving mechanical ventilation reduced the risk of progressing to mechanical ventilation or death (33% vs 38% SOC). Similar to the REMAP-CAP trial, the majority (82%) of patients were receiving corticosteroids at baseline, and the mortality benefit of tocilizumab was not seen in patients not receiving corticosteroids [13] . 

Regeneron Pharmaceuticals employee and current stockholder, and reports grants from Table 1 

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

COVID-19: consider cytokine storm syndromes and immunosuppression

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China

An inflammatory cytokine signature helps predict COVID-19 severity and death

Effective treatment of severe COVID-19 patients with tocilizumab

Tocilizumab treatment in COVID-19: A single center experience

Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in

COVID-19 pneumonia treated with Sarilumab: a clinical series of eight patients

Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy

Tocilizumab treatment for cytokine release syndrome in hospitalized COVID-19 patients: survival and clinical outcomes

Interleukin-6 receptor antagonists in critically ill patients with Covid-19 -preliminary report

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial

Regeneron Pharmaceuticals Inc. Regeneron and Sanofi provide update on US Phase 2/3 adaptive-designed trial of KEVZARA® (sarilumab) in hospitalized COVID-19 pateints

Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization

Long-term safety of sarilumab in

The authors thank the patients, their families, and investigational site members involved in this study (principal investigators and subprincipal investigators listed in the